公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
2017 | National policies fostering hospice care increased hospice utilization and reduced the invasiveness of end-of-life care for cancer patients | YU-YUN SHAO ; Hsiue E.H.-C.; CHIH-HUNG HSU ; CHIEN-AN YAO ; Chen H.-M.; Lai M.-S.; ANN-LII CHENG | Oncologist | 21 | 17 | |
2019 | Neutrophil-to-lymphocyte Ratio and Use of Antibiotics Associated With Prognosis in Esophageal Squamous Cell Carcinoma Patients Receiving Immune Checkpoint Inhibitors | JHE-CYUAN GUO ; CHIA-CHI LIN ; Lin, Chen Yuan; MIN-SHU HSIEH ; HUNG-YANG KUO ; Lien, Ming Yu; YU-YUN SHAO ; Ta-Chen Huang ; CHIH-HUNG HSU | Anticancer research | 28 | 29 | |
2022 | Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma | Doki, Yuichiro; Ajani, Jaffer A; Kato, Ken; Xu, Jianming; Wyrwicz, Lucjan; Motoyama, Satoru; Ogata, Takashi; Kawakami, Hisato; CHIH-HUNG HSU ; Adenis, Antoine; El Hajbi, Farid; Di Bartolomeo, Maria; Braghiroli, Maria I; Holtved, Eva; Ostoich, Sandra A; Kim, Hye R; Ueno, Masaki; Mansoor, Wasat; Yang, Wen-Chi; Liu, Tianshu; Bridgewater, John; Makino, Tomoki; Xynos, Ioannis; Liu, Xuan; Lei, Ming; Kondo, Kaoru; Patel, Apurva; Gricar, Joseph; Chau, Ian; Kitagawa, Yuko | The New England journal of medicine | 333 | 302 | |
2019 | Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial | Kato K.; Cho B.C.; Takahashi M.; Okada M.; Lin C.-Y.; Chin K.; Kadowaki S.; Ahn M.-J.; Hamamoto Y.; Doki Y.; Yen C.-C.; Kubota Y.; Kim S.-B.; CHIH-HUNG HSU ; Holtved E.; Xynos I.; Kodani M.; Kitagawa Y. | The Lancet Oncology | 722 | 630 | |
2013 | Nuclear expression of glioma-associated oncogene homolog 1 and nuclear factor-κb is associated with a poor prognosis of pancreatic cancer | SHIH-HUNG YANG ; CHIH-HUNG HSU ; JEN-CHIEH LEE ; YU-WEN TIEN ; SUNG-HSIN KUO ; ANN-LII CHENG | Oncology (Switzerland) | 24 | 20 | |
2018 | Number of resected lymph nodes and survival of patients with locally advanced esophageal squamous cell carcinoma receiving preoperative chemoradiotherapy | JHE-CYUAN GUO ; CHIA-CHI LIN ; Ta-Chen Huang ; PEI-MING HUANG ; HUNG-YANG KUO ; Chang C.-H.; CHIA-CHUN WANG ; CHIA-HSIEN CHENG ; KUN-HUEI YEH ; CHIH-HUNG HSU ; JANG-MING LEE | Anticancer Research | 12 | 11 | |
2017 | On predicting clinical response to chemoradiotherapy in esophageal squamous cell carcinoma: Additional evaluation by magnetic resonance imaging may help | Ta-Chen Huang ; CHIH-HUNG HSU | Annals of Translational Medicine | 0 | 0 | |
2008 | OSU-03012, a novel celecoxib derivative, induces reactive oxygen species-related autophagy in hepatocellular carcinoma | Gao M.; Yeh P.Y.; YEN-SHEN LU ; CHIH-HUNG HSU ; Chen K.-F.; Lee W.-C.; Feng W.-C.; Chen C.-S.; Kuo M.-L.; ANN-LII CHENG | Cancer Research | 131 | 123 | |
2008 | Outcome of advanced nonsmall cell lung cancer patients receiving gemcitabine and weekly paclitaxel as first-line treatment | ZHONG-ZHE LIN ; CHIUN HSU ; YEUN-CHUNG CHANG ; CHONG-JEN YU ; CHIH-HUNG HSU ; CHIA-CHI LIN ; ANN-LII CHENG ; PAN-CHYR YANG ; CHIH-HSIN YANG | Lung Cancer | 5 | 1 | |
2002 | P53 Overexpression predicts poor chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV colorectal cancers after palliative bowel resection | JIN-TUNG LIANG ; KUO-CHIN HUANG ; Cheng Y.-M.; Hsu H.-C.; ANN-LII CHENG ; CHIH-HUNG HSU ; KUN-HUEI YEH ; Wang S.-M.; KING-JEN CHANG | International Journal of Cancer | 66 | 57 | |
2020 | Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS–ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO | Chen L.-T.; Martinelli E.; ANN-LII CHENG ; Pentheroudakis G.; Qin S.; Bhattacharyya G.S.; Ikeda M.; Lim H.-Y.; Ho G.F.; Choo S.P.; Ren Z.; Malhotra H.; Ueno M.; Ryoo B.-Y.; Kiang T.C.; Tai D.; Vogel A.; Cervantes A.; Lu S.-N.; Yen C.-J.; Huang Y.-H.; Chen S.-C.; CHIUN HSU ; YING-CHUN SHEN ; Tabernero J.; Yen Y.; CHIH-HUNG HSU ; Yoshino T.; Douillard J.-Y. | Annals of Oncology | 117 | 112 | |
2015 | Pathological stage after neoadjuvant chemoradiation and esophagectomy superiorly predicts survival in patients with esophageal squamous cell carcinoma | CHIA-CHUN WANG ; CHIA-HSIEN CHENG ; CHIAO-LING TSAI ; JANG-MING LEE ; PEI-MING HUANG ; CHIA-CHI LIN ; CHIH-HUNG HSU ; MIN-SHU HSIEH ; YIH-LEONG CHANG ; Feng-Ming Hsu | Radiotherapy and Oncology | 9 | 8 | |
2006 | A pathway for tumor necrosis factor-α-induced Bcl10 nuclear translocation: Bcl10 is up-regulated by NF-κB and phosphorylated by Akt1 and then complexes with Bcl3 to enter the nucleus | Pei Y.Y.; SUNG-HSIN KUO ; KUN-HUEI YEH ; Chuang S.-E.; CHIH-HUNG HSU ; Wen C.C.; Lin H.-I.; Gao M.; ANN-LII CHENG | Journal of Biological Chemistry | 43 | 39 | |
2022 | Pembrolizumab versus chemotherapy for patients with esophageal squamous cell carcinoma enrolled in the randomized KEYNOTE-181 trial in Asia | Cao, Y; Qin, S; Luo, S; Li, Z; Cheng, Y; Fan, Y; Sun, Y; Yin, X; Yuan, X; Li, W; Liu, T; CHIH-HUNG HSU ; Lin, X; Kim, S-B; Kojima, T; Zhang, J; Lee, S-H; Bai, Y; Muro, K; Doi, T; Bai, C; Gu, K; Pan, H-M; Bai, L; Yang, J-W; Cui, Y; Lu, W; Chen, J | ESMO open | 24 | 18 | |
2000 | Persistent severe hypocapnia and alkalemia in a 40-year-old woman | CHIA-HSUIN CHANG ; PING-HUNG KUO ; CHIH-HUNG HSU ; PAN-CHYR YANG | Chest | 8 | 6 | |
2016 | Perspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancer | SHIH-HUNG YANG ; TING-CHUN KUO ; Wu H.; JHE-CYUAN GUO ; CHIUN HSU ; CHIH-HUNG HSU ; YU-WEN TIEN ; KUN-HUEI YEH ; ANN-LII CHENG ; SUNG-HSIN KUO | World Journal of Gastroenterology | 24 | 25 | |
2001 | Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions | ANN-LII CHENG ; CHIH-HUNG HSU ; Lin J.-K.; Hsu M.-M.; YUNN-FANG HO ; She T.-S.; JENG-YUH KO ; Lin J.-T.; BOR-RU LIN ; MING-SHIANG WU ; Yu H.-S.; SHIOU-HWA JEE ; Chen G.-S.; Chen T.-M.; CHI-AN CHEN ; Lai M.-K.; YEONG-SHIAU PU ; MIN-HSIUNG PAN ; Wang Y.-J.; Tsai C.-C.; CHANG-YAO HSIEH | Anticancer Research | 1925 | 1695 | |
2020 | A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors | JIH-HSIANG LEE ; WEI-WU CHEN ; CHIH-HUNG HSU ; Yen Y.-H.; CHIH-HSIN YANG ; ANN-LII CHENG ; Sasaki S.-I.; Chiu L.Y.; Sugihara M.; Ishizuka T.; Oguma T.; Tajima N.; CHIA-CHI LIN | Investigational New Drugs | 39 | 36 | |
2014 | A phase i study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies | CHIA-CHI LIN ; Su W.-C.; Yen C.-J.; CHIH-HUNG HSU ; Su W.-P.; KUN-HUEI YEH ; YEN-SHEN LU ; ANN-LII CHENG ; Huang D.C.-L.; Fritsch H.; Voss F.; Taube T.; CHIH-HSIN YANG | British Journal of Cancer | 62 | 64 | |
2006 | Phase I-II trial of weekly gemcitabine plus high-dose 5-fluorouracil and leucovorin in advanced pancreatic cancer | Shiah H.-S.; ANN-LII CHENG ; CHIUN HSU ; CHIH-HUNG HSU ; Liu T.-W.; Chang J.-Y.; Jan C.-M.; Chao Y.; Yu W.-L.; Chuang T.-R.; Whang-Peng J.; Chen L.-T. | Journal of Gastroenterology and Hepatology (Australia) | 6 | 5 | |